KR101534755B1 - Composition for anti-allergy containing oriental raisin tree extract - Google Patents
Composition for anti-allergy containing oriental raisin tree extract Download PDFInfo
- Publication number
- KR101534755B1 KR101534755B1 KR1020130101689A KR20130101689A KR101534755B1 KR 101534755 B1 KR101534755 B1 KR 101534755B1 KR 1020130101689 A KR1020130101689 A KR 1020130101689A KR 20130101689 A KR20130101689 A KR 20130101689A KR 101534755 B1 KR101534755 B1 KR 101534755B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- present
- production
- inhibit
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 239000000284 extract Substances 0.000 title claims abstract description 57
- 230000003266 anti-allergic effect Effects 0.000 title description 5
- 240000006365 Vitis vinifera Species 0.000 title description 3
- 235000014787 Vitis vinifera Nutrition 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 claims description 34
- 208000026935 allergic disease Diseases 0.000 claims description 31
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 26
- 230000007815 allergy Effects 0.000 claims description 23
- 206010020751 Hypersensitivity Diseases 0.000 claims description 22
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 14
- 229960001340 histamine Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 201000008937 atopic dermatitis Diseases 0.000 claims description 10
- 244000010000 Hovenia dulcis Species 0.000 claims description 9
- 235000008584 Hovenia dulcis Nutrition 0.000 claims description 9
- 102000015696 Interleukins Human genes 0.000 claims description 7
- 108010063738 Interleukins Proteins 0.000 claims description 7
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
- 208000003455 anaphylaxis Diseases 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 3
- 206010057380 Allergic keratitis Diseases 0.000 claims description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 3
- 208000028185 Angioedema Diseases 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 230000036783 anaphylactic response Effects 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- 108010082169 Chemokine CCL17 Proteins 0.000 claims description 2
- 239000000287 crude extract Substances 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 102000003826 Chemokine CCL17 Human genes 0.000 claims 1
- 230000000694 effects Effects 0.000 description 25
- 210000003630 histaminocyte Anatomy 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000013566 allergen Substances 0.000 description 12
- 239000008187 granular material Substances 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 108010012236 Chemokines Proteins 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 8
- 238000013329 compounding Methods 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- -1 coloring Substances 0.000 description 6
- 238000004040 coloring Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000002438 mitochondrial effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 4
- 230000006433 tumor necrosis factor production Effects 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 241000758405 Zoopagomycotina Species 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 235000006751 Platycodon Nutrition 0.000 description 2
- 244000274050 Platycodon grandiflorum Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 2
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229930189914 platycodon Natural products 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 101710112538 C-C motif chemokine 27 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000003912 basophilic leucocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000014491 negative regulation of interleukin-4 production Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 지구자 추출물을 포함하는 조성물에 관한 것이다. The present invention relates to a composition comprising a platelet extract.
Description
본 발명은 지구자 추출물을 포함하는 조성물에 관한 것이다.
The present invention relates to a composition comprising a platelet extract.
현대사회는 점점 복잡해지고 산업과 문명의 발달로 인해 자연환경오염의 증가, 식생활의 변화, 스트레스의 가중 등으로 인해 알러지성 질환이 매년 증가하고 있다. 최근, 대한 소아알레르기 호흡기학회에서 '어린이 청소년 소년 알레르기 질환 국제역학조사(ISAAC)' 설문지를 이용하여 조사한 바에 따르면, 아토피성 피부질환은 1995년에는 초등학생의 16.3%, 중학생의 7.3%로 나타난 데 반해 2000년에는 각각 24.9%와 12.8%로 증가하였음을 알 수 있다. Modern society is becoming increasingly complex, and due to the development of industry and civilization, allergic diseases are increasing every year due to increased pollution of natural environment, change of diet, and stress. Recently, the National Institute of Allergy and Respiratory Diseases of Japan (ISAAC) conducted a survey of children with juvenile allergic disease (ISAAC), which found that 16.3% of elementary school students and 7.3% of middle school students had atopic skin diseases in 1995 In 2000, it increased to 24.9% and 12.8% respectively.
비만세포 및 혈중 호염구는 여러가지 알러지(allergy) 질환 즉, 아토피 피부염, 알러지 비염, 천식, 음식 알러지 및 아나필락틱 쇼크 등을 유발하는 주요한 체내 세포로 알려져 있다. 이들 세포는 세포표면에 알러지를 유발하는 항체인 IgE에 대한 수용체(FcεRI)를 가지고 있고, 이러한 수용체는 알러지를 유발하는 물질(항원, allergen)에 의해 자극을 받아 자신이 가지고 있는 히스타민(histamine), 프로스타글란딘(prostaglandin), 루코트리엔(leukotriene) 등 다양한 알러지를 유발, 심화시키는 물질들을 세포 바깥으로 분비한다(Kim K. et al., Eur. J. Pharmacol., 581:191-203, 2008). Mast cells and blood neutrophils are known to be major body cells that cause various allergic diseases such as atopic dermatitis, allergic rhinitis, asthma, food allergy and anaphylactic shock. These cells have a receptor for IgE (FcεRI), an antibody that induces allergy on the cell surface. These receptors are stimulated by allergens (antigens, allergens) (Kim K. et al., Eur. J. Pharmacol., 581: 191-203, 2008), which secretes substances that induce and deepen various allergies such as prostaglandins and leukotrienes. .
한편, 알러지성 질환으로 잘 알려진 아토피에 대한 연구들에서, 케모카인(chemokine)들에 의한 아토피 피부염의 발생이 또한 보고되었다. 이들 케모카인들도 세포에서 발현되는 단백질인 것에서는 상기한 싸이토카인(cytokine)과 동일한데 그 작용은 약간 다른 것으로 알려지고 있다. 즉, 상기 케모카인들은 주로 특정 부위로 특정한 세포들을 불러 모으는 역할을 한다. 즉 어떤 세포가 특정 케모카인을 발현하게 되면 그 케모카인에 반응하는 종류의 세포들이 상기 케모카인이 발현된 세포 쪽으로 이동하게 되어, 일종의 집합 신호 역할을 한다고 알려지고 있다. 특히, 다양한 종류의 백혈구의 이동과 활성화를 조절하는 싸이토카인의 일종으로, 조직으로의 염증세포의 침윤을 조절한다. 구체적으로 알려진 케모카인들로서는 CCL22/MDC 및 CCL17/TARC(T-세포의 회복 및 촉발 ; 인터루킨 4, 인터루킨 5, 인터루킨 13 및 TNF-α의 T-세포 생성), TSLP(TARC 및 MDC의 증가된 생성의 결과를 가져오는 수지상 세포의 활성화), CCL27/CTACK(림프구의 회복 및 이동) 및 RANTES(호산구 및 T-세포 이동/활성화 ; 내피세포 표면에의 호산구 부착의 증가) 등이 있다. On the other hand, in studies of atopy, well known for allergic diseases, the incidence of atopic dermatitis by chemokines has also been reported. These chemokines are also the same as the cytokines described above in terms of the proteins expressed in cells, and their actions are known to be slightly different. That is, the chemokines mainly collect specific cells to specific sites. That is, when a certain cell expresses a specific chemokine, the kind of cells that respond to the chemokine is moved toward the chemokine-expressing cell, and it is known that it acts as a sort of aggregation signal. In particular, it is a type of cytokine that regulates the migration and activation of various types of white blood cells, and regulates the infiltration of inflammatory cells into tissues. Specific known chemokines include CCL22 / MDC and CCL17 / TARC (recovery and triggering of T-cells; interleukin 4,
현재 알러지를 치료하는 다양한 방법들이 존재하지만, 대부분 그 원인을 근본적으로 없애기보다는 증상을 완화시키는 것에 불과하다. 대표적으로 알러지의 치료를 위해서, 알러젠에 의해 비만세포 등에서 분비된 히스타민이나 류코트리엔 등의 수용체에 대한 길항체를 그 성분으로 하는 약들이 사용되고 있다. 그러나 이러한 약물은 환자에게 투여하면, 단기간 내에 내성을 나타내기 때문에, 일정기간 이상 또는 반복하여 투여시 환자의 증상을 최초 복용시처럼 호전시킬 수 없다는 문제점이 있다.Currently, there are various ways to treat allergies, but most of them are merely symptomatic relief rather than fundamentally eliminating the cause. Typically, for the treatment of allergies, medicines containing antagonists against histamine or leukotriene such as histamine or leukotriene secreted from allergens by mast cells are used. However, since such a drug shows tolerance within a short period of time when administered to a patient, there is a problem that the patient's symptoms can not be improved as in the case of the first administration when administered over a period of time or repeatedly.
지구자는 다양한 약리활성을 가지고 있어 항산화 활성, 간보호 활성 등이 학계에 보고된바 있다 (Hase et al., 1997, Biol. Pharm. Bull., 20(4) 381-385). 그러나 아토피 피부염, 비염, 천식과 같은 알러지성 질환의 억제 효능은 전혀 보고된 바 없다.
Biol. Pharm. Bull., 20 (4) 381-385) have been reported in academia because of their diverse pharmacological activities. However, the inhibitory effect of allergic diseases such as atopic dermatitis, rhinitis and asthma has not been reported at all.
본 발명의 목적은 항알러지용 조성물을 제공하는 것이다.
It is an object of the present invention to provide a composition for anti-allergy.
상기 목적을 달성하기 위해 본 발명은 지구자 추출물을 유효성분으로 포함하는 알러지 질환의 예방, 치료, 개선 또는 완화용 조성물을 제공한다.
To achieve the above object, the present invention provides a composition for preventing, treating, ameliorating or alleviating an allergic disease, which comprises a platelet derived extract as an active ingredient.
본 발명의 조성물은 지구자 추출물을 유효성분으로 포함하여, 비만세포의 과립 내 존재하는 알러지 유발물질의 분비를 억제할 수 있고, 히스타민 생성을 억제하며, TNF-α의 생성을 억제할 수 있고, 인터루킨의 생성을 억제할 뿐 아니라, 인체 각질형성세포에서 TARC의 생성을 억제할 수 있어서, 알러지 질환의 예방, 치료, 개선 또는 완화에 유용하게 사용될 수 있다. The composition of the present invention can inhibit the secretion of allergen-inducing substances present in the granules of mast cells, inhibit histamine production, inhibit the production of TNF-α, It is possible to inhibit the production of interleukin and inhibit the production of TARC in human keratinocytes and thus can be usefully used for the prevention, treatment, improvement or alleviation of allergic diseases.
기존 알러지 치료 등의 제제는 이미 생성되어 분비된 알러지 유발 물질의 수용체에 대한 길항체를 그 성분으로 하여, 알러지의 원인을 근본적으로 해결할 수 없지만, 본 발명 조성물은 알러지의 원인이 되는 알러지 유발 물질의 생성 자체를 억제할 수 있어서, 알러지 예방 등을 위한 근원적인 해결책이 될 수 있다. 그러므로 본 발명의 조성물은 알러지성 질환의 구체적인 예시인 천식, 아토피성 피부질환, 비염 등의 예방 및 치료에 우수한 효능을 가지는 조성물로서 유용하게 사용될 수 있다. Although the conventional medicines such as the allergic treatment can not fundamentally solve the cause of allergy by using the antagonistic antibody against the receptor of the allergen-induced substance already generated and secreted, the composition of the present invention can be used as an allergen- It is possible to suppress the generation itself, which can be a fundamental solution for prevention of allergy and the like. Therefore, the composition of the present invention can be effectively used as a composition having an excellent effect for the prevention and treatment of asthma, atopic skin diseases, rhinitis, etc., which are specific examples of allergic diseases.
아울러, 본 발명 조성물의 유효성분인 지구자는 예전부터 열매, 줄기, 잎 등을 생으로 먹거나 달여서 먹었을 만큼 생물체에 무해하므로, 이를 포함하는 본원발명 조성물은 생체 적용시에도 부작용이 없고 안정성이 뛰어나다. 아울러, 알러지 질환의 치료 등을 위해 화합물 성분의 약제를 사용하는 경우, 내성이 쉽게 생기는 반면, 본원발명 조성물은 자연 유래의 추출물을 포함하여 장기간 복용시에도 내성이 없다.
In addition, since the globule which is an effective component of the composition of the present invention is harmless to an organism such that it is eaten raw or dalyeoseo fruit, stem, and leaf from the past, the composition of the present invention has no side effects and has excellent stability even when applied to a living body. In addition, when a medicament of a compound component is used for the treatment of an allergic disease or the like, resistance to the medicament easily occurs, but the composition of the present invention is not resistant to long-term administration including natural extracts.
도 1은 지구자 추출물이 비만세포의 과립 내 존재하는 알러지 유발물질의 분비를 억제함을 확인한 결과이다.
도 2는 지구자 추출물이 비만세포에서 히스타민 생성을 억제함을 확인한 결과이다.
도 3은 지구자 추출물이 비만세포에서 TNF-α의 생성을 억제함을 확인한 결과이다.
도 4는 지구자 추출물이 비만세포에서 인터루킨-4 생성을 억제함을 확인한 결과이다.
도 5는 지구자 추출물이 인체 각질형성세포에서 TARC의 생성을 억제함을 확인한 결과이다. FIG. 1 shows the results of confirming that the Zygomycota extract inhibits the secretion of allergen-inducing substances present in the granules of mast cells.
FIG. 2 shows the results of confirming that the mitochondrial extract inhibits histamine production in mast cells.
FIG. 3 shows the results of confirming that the mitochondrial extract inhibits TNF-α production in mast cells.
FIG. 4 shows the result of confirming that the endogenous extract inhibits interleukin-4 production in mast cells.
FIG. 5 shows the results obtained by confirming that the endoplasmic reticulum extract inhibits TARC production in human keratinocytes.
본 발명은 일 관점에서, 지구자 추출물을 유효성분으로 포함하는 알러지 예방 또는 치료용 약학 조성물에 관한 것이다. In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating allergy, which comprises a platelet extract as an active ingredient.
본 명세서에서 "지구자"는 지구자는 영문명 Oriental Raisin Tree, 학명 Hovenia dulcis을 가지는 식물을 의미하는 것으로, 헛개나무, 호리깨나무, 볼게나무 등으로도 불리운다. 지구자의 잎은 어긋나고 넓은 달걀모양 또는 타원모양으로 가장자리에 잔거치가 있으며, 열매는 9~10월에 익으며 둥근모양이고 갈색을 띤다. In the present specification, the term "earth" means a plant having the English name Oriental Raisin Tree, the scientific name Hovenia dulcis , and is also called hinoki, hinoki, kokuga, and the like. The leaves of the earth are alternate, broad ovate or elliptical shape, and there is a grapevine on the edge. The fruit ripens from September to October and is round and brownish.
본 명세서에서 사용하는 지구자는 그 입수 방법에 제한이 없으며, 재배하여 사용하거나 시판되는 것을 구입하여 사용할 수도 있다. 아울러 본 명세서에서 사용하는 지구자는 지구자의 지상부 또는 지하부의 일부 또는 전부를 함께 사용할 수 있으나, 구체적으로 지구자의 줄기 부분만을 이용할 수 있다. The geographer used in the present specification is not limited to the method of obtaining the geographical information. In addition, the geographer used in this specification may use the ground portion of the geographical portion or a part or all of the ground portion together, but specifically, only the stem portion of the geographer can be used.
본 명세서에서 "유효성분"은 단독으로 목적하는 활성을 나타내거나 또는 그 자체 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미하는 것이다.As used herein, the term " active ingredient "alone refers to an ingredient that exhibits the desired activity or that can exhibit activity with a carrier that is not itself active.
본 명세서에서 "지구자 추출물"은 물, C1-C6 알콜, 및 이들이 조합으로 구성된 그룹에서 선택된 용매의 조추출물일 수 있다. 상기 C1-C6 알콜은 구체적으로 메탄올 또는 에탄올일 수 있다. 상기 추출물을 제조하는 방법은 초임계추출, 아임계추출, 고온추출, 고압추출 또는 초음파추출법 등의 추출장치를 이용한 방법 또는 XAD 및 HP-20을 포함한 흡착 수지를 이용하는 방법 등 당업계의 통상적인 추출방법을 사용할 수 있다. 구체적으로, 가온하며 환류 추출 또는 상온에서 추출할 수 있으나, 이에 제한되지 않는다. 아울러, 추출 회수는 1 내지 5회일 수 있으나, 구체적으로 3회 반복 추출할 수 있으며, 이에 한정하는 것은 아니다. 추출 시간은 2 내지 12시간일 수 있고, 구체적으로 3시간 내지 5시간일 수 있으나, 이에 제한되는 것은 아니다. 아울러, 상기 추출 이후 농축 또는 동결건조 등의 방법을 추가적으로 거칠 수 있다.As used herein, "platelet extract" may be a crude extract of a solvent selected from the group consisting of water, C 1 -C 6 alcohols, and combinations thereof. The C 1 -C 6 alcohol may specifically be methanol or ethanol. The method for preparing the extract may be a conventional extraction method such as supercritical extraction, subcritical extraction, high-temperature extraction, high-pressure extraction, ultrasonic extraction, or the like using XAD and HP-20 adsorbent resins. Method can be used. Specifically, it may be warmed and refluxed or extracted at room temperature, but is not limited thereto. In addition, the number of times of extraction may be 1 to 5 times, but may be repeated three times, but is not limited thereto. The extraction time may be 2 to 12 hours, and may be 3 to 5 hours, but is not limited thereto. Further, after the extraction, a method such as concentration or lyophilization may be additionally carried out.
본 명세서에서 "알러지"는 생물체가 어떤 외래성 물질(allergen)과 접하게 되면 항원항체반응에 의하여 보이는 생체 내에 급격한 반응 변화 현상을 총칭한다. 본 명세서에서 상기 외래성 물질의 종류에는 제한이 없으며, 구체적으로 꽃가루, 약물, 식물성 섬유, 세균, 음식물, 염색약 또는 화학물질 등을 포함할 수 있으나, 이에 제한되는 것은 아니다. 본 명세서에서는 상기 외래성 물질로 인해 변화를 보이는 신체의 특정 부위를 제한하지 않는다. 아울러 상기 알러지는 외래성 물질에 의해 발생하는 생체 내의 변화에 의해 유발되는 신체의 변화를 총칭하는 것으로 알러지 질환을 의미할 수 있다. 구체적으로 상기 알러지는 알러지 비염(allergic rhinitis), 알러지 천식(bronchial asthma), 고초열(hay fever), 퀸케부종(Quincke's edema), 아나필락시스(anaphylaxis) 쇼크, 두드러기(hives), 알러지성 결막염 (allergic conjunctivitis), 알러지성 각막염 (allergic keratitis) 또는 아토피 피부염(atopic dermatitis)과 같은 질환을 포함할 수 있으나, 이에 제한되는 것은 아니며, 외래성 물질에 의해 생체가 보이는 변화를 모두 포함한다. In the present specification, "allergy" refers to a sudden change in the reaction phenomenon observed in an organism when an organism comes into contact with an allergen. In this specification, there is no limitation on the kind of the adventitious substance, and it may include, but not limited to, pollen, drug, vegetable fiber, bacteria, food, dye or chemical. The present specification does not limit the specific region of the body that is changed by the adventitious substance. In addition, the allergy refers to a change in the body caused by a change in a living body caused by an adventitious substance, which may mean allergic disease. Specifically, the allergic agent is selected from the group consisting of allergic rhinitis, bronchial asthma, hay fever, Quincke's edema, anaphylaxis shock, hives, allergic conjunctivitis, ), Allergic keratitis, or atopic dermatitis, but are not limited to, and include all visible changes in the body by adventitious agents.
본 명세서에서 "알러지 질환의 예방 또는 치료용"이란, 알러지와 관련된 질환의 예방 또는 상기 질환의 치료 용도를 모두 포함하는 것이다. 예방 또는 치료의 방법에는 제한이 없으며, 구체적으로 알러지 유발물질 등의 생성을 근본적으로 억제하여 상기 질환을 예방할 수 있으나 이에 제한되는 것은 아니다.As used herein, the term "for the prevention or treatment of allergic diseases " includes all uses for the prevention of diseases associated with allergy or for the treatment of the diseases. There is no limitation on the method of prevention or treatment, and the production of allergen-inducing substances and the like can be fundamentally inhibited to prevent the disease, but the present invention is not limited thereto.
본 발명에 따른 조성물을 의약품에 적용할 경우에는, 상기 조성물을 유효성분으로 하여 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여제 혹은 비경구 투여제로 제제화 할 수 있다.When the composition according to the present invention is applied to medicines, it may be formulated into an oral or parenteral dosage form in the form of solid, semi-solid or liquid by adding an inorganic or organic carrier to the composition as an active ingredient.
상기 경구 투여를 위한 제재로서는 정제, 환제, 과립제, 캡슐제, 산제, 세립제, 분제, 유탁제, 시럽제, 펠렛제 등을 들 수 있다. 또한, 상기 비경구 투여를 위한 제재로는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제, 좌제 등을 들 수 있다. 본 발명의 유효성분을 제제화하기 위해서는 상법에 따라서 실시하면 용이하게 제제화할 수 있으며 계면활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제, 기타 상용하는 보조제를 적당히 사용할 수 있다.Examples of the agent for oral administration include tablets, pills, granules, capsules, powders, fine granules, powders, emulsions, syrups and pellets. Examples of the parenteral administration agent include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. In order to formulate the active ingredient of the present invention, it can be easily formulated according to the conventional method. Surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffering agents, suspending agents and other adjuvants can be suitably used.
본 발명에 따른 상기 약학 조성물은 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다. The pharmaceutical composition according to the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously and the like.
본 발명의 약학 조성물의 유효 성분은 투여 받을 대상의 연령, 성별, 체중, 병리 상태 및 그 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 적용량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1mg/kg/일 내지 100mg/kg/일, 보다 구체적으로는 5 mg/kg/일 내지 50 mg/kg/일이 될 수 있으나, 이에 제한되는 것은 아니다.The effective ingredients of the pharmaceutical composition of the present invention will vary depending on the age, sex, weight, pathological condition and severity of the subject to be treated, administration route or judgment of the prescriber. Determination of the amount of application based on these factors is within the level of ordinary skill in the art and its daily dose is, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / / Day, but is not limited thereto.
본 발명은 다른 관점에서, 지구자 추출물을 유효성분으로 포함하는 알러지의 예방 또는 개선용 식품 조성물에 관한 것이다. In another aspect, the present invention relates to a food composition for preventing or alleviating allergies comprising an extract from Jurassicore as an active ingredient.
본 명세서에서 상기 "알러지 예방 또는 개선용"이란 알러지 질환의 정도를 낮추어주거나 완화시키는 용도를 포함하는 것이다. 구체적으로, 이미 발생한 알러지 질환의 정도를 낮추어주거나 완화시키는 것을 포함할 수 있고, 본원발명 조성물이 알러지의 원인물질을 근본적으로 억제한다는 것을 생각하면 알러지 질환의 예방도 가능할 수 있다. As used herein, the term "for the prevention or improvement of allergy" includes the use of lowering or alleviating the degree of allergy disease. Specifically, it may include lowering or alleviating the degree of the already-occurring allergic disease, and prevention of allergic diseases may be possible by considering that the composition of the present invention fundamentally suppresses allergen causative substances.
상기 조성물은 이를 포함하는 드링크제, 발효유, 치즈, 요구르트, 주스, 생균제제 및 건강보조식품 등으로 가공될 수 있으며, 그 외 다양한 식품 첨가제의 형태로 사용될 수 있다. The composition may be processed into a drink, fermented milk, cheese, yogurt, juice, probiotic agent, and health supplement food or the like, and may be used in various other food additives.
일실시예에서 상기 조성물은, 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 주 효과에 상승 효과를 줄 수 있는 다른 성분 등을 함유할 수 있다. 예를 들어, 물성 개선을 위하여 향료, 색소, 살균제, 산화방지제, 방부제, 보습제, 점증제, 무기염류, 유화제 및 합성 고분자 물질 등의 첨가제를 더 포함할 수 있다. 그 외에도, 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당 및 해초 엑기스 등의 보조 성분을 더 포함할 수도 있다. 상기 성분들은 제형 또는 사용 목적에 따라서 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 그 첨가량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. In one embodiment, the composition may contain other ingredients or the like that can give synergistic effects to the main effect within a range that does not impair the intended main effect of the present invention. For example, additives such as perfume, coloring agent, bactericide, antioxidant, preservative, moisturizing agent, thickening agent, inorganic salt, emulsifier and synthetic polymer substance may be further added for improvement of physical properties. In addition, it may further contain auxiliary components such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides and seaweed extract. The above components may be mixed and selected without difficulty by those skilled in the art depending on the purpose of formulation or use, and the amount thereof may be selected within a range that does not impair the objects and effects of the present invention.
본 발명에 따른 조성물의 제형은 용액, 유화물, 점성형 혼합물, 타블렛, 분말 등의 다양한 형태일 수 있으며, 이는 단순 음용, 주사 투여, 스프레이 방식 또는 스퀴즈 방식 등의 다양한 방법으로 투여될 수 있다. The composition according to the present invention may be in various forms such as a solution, an emulsion, a viscous mixture, a tablet, a powder, etc., and may be administered by various methods such as simple drinking, injection administration, spraying or squeezing.
본원발명의 일 관점인 상기 건강식품 조성물은 투여 방식과 무관하게 대상의 항알러지 효과를 가져온다. 구체적으로 상기 조성물을 경구투여하는 경우에도 대상의 항알러지 효과를 관찰할 수 있다. The health food composition, which is an aspect of the present invention, brings about an antiallergic effect of the subject irrespective of the administration mode. Specifically, when the composition is orally administered, the antiallergic effect of the subject can be observed.
본 발명은 또 다른 관점에서, 지구자 추출물을 유효성분으로 포함하는 알러지 개선 또는 완화용 화장료 조성물에 관한 것이다.In another aspect, the present invention relates to a cosmetic composition for alleviating or alleviating allergies, which comprises a platelet extract as an active ingredient.
본 명세서에서 상기 "알러지 개선 또는 완화용"이란 알러지 질환의 정도를 낮추어주거나 완화시키는 용도를 포함하는 것이다. 구체적으로, 이미 발생한 알러지 질환의 정도를 낮추어주거나 완화시키는 것을 포함할 수 있고, 본원발명 조성물이 알러지의 원인물질을 근본적으로 억제한다는 것을 생각하면 알러지 질환의 예방도 가능할 것이나, 이에 제한되지 않는다.As used herein, the term "for alleviating or alleviating allergy " includes the use of lowering or alleviating the degree of allergic diseases. Specifically, it may include lowering or alleviating the degree of the already-occurring allergic disease, and considering that the composition of the present invention is fundamentally inhibiting the causative substance of allergy, prevention of allergic diseases is also possible but is not limited thereto.
본 발명에 따른 화장료 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있다. 예를 들면, 용액, 수상에 유상을 분산시켜 얻은 에멀젼, 유상에 수상을 분산시켜 얻은 에멀젼, 현탁액, 고체, 겔, 분말, 페이스트, 포말(foam) 또는 에어로졸 조성물의 제형으로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.The cosmetic composition according to the present invention may be provided in all formulations suitable for topical application. For example, it may be provided as a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an oil phase in water, a suspension, a solid, a gel, a powder, a paste, a foam or an aerosol composition. Compositions of such formulations may be prepared according to conventional methods in the art.
본 발명에 따른 화장료 조성물은 상기한 물질 이외에 주 효과를 손상시키지 않는 범위 내에서, 바람직하게는 주 효과에 상승 효과를 줄 수 있는 다른 성분들을 포함할 수 있다. 또한 본 발명에 따른 화장료 조성물은 보습제, 에몰리언트제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 냉감제 또는 제한제를 더 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 전체 중량을 기준으로 0.01 내지 5 중량%, 구체적으로 0.01 내지 3 중량%일 수 있다.The cosmetic composition according to the present invention may contain, in addition to the above-mentioned substances, other ingredients which can give a synergistic effect to the main effect, so long as they do not impair the main effect. The cosmetic composition according to the present invention may further comprise a moisturizing agent, an emollient agent, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjuster, an organic and inorganic pigment, a fragrance, a cold agent or a limiting agent. The compounding amount of the above components can be easily selected by those skilled in the art within a range not to impair the objects and effects of the present invention. The amount thereof may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight, have.
본 발명의 일 관점인 조성물에 있어서, 상기 지구자 추출물은 호베니아 덜시스 (Hovenia dulcis) 줄기의 추출물일 수 있다. In one aspect of the invention, the platelet extract is selected from the group consisting of Hovenia dulcis ) stem.
구체적으로, 본 발명의 일 관점인 조성물에 있어서, 상기 지구자는 호베니아 덜시스 (Hovenia dulcis)일 수 있다. Specifically, in a composition that is an aspect of the invention, the globular is selected from the group consisting of Hovenia dulcis .
아울러, 상기 추출물은 호베니아 덜시스 (Hovenia dulcis) 의 지상부 또는 지하부를 제한없이 사용하여 추출할 수 있으나, 줄기 부분 추출물의 항알러지 효과가 우수하므로, 구체적으로 줄기 부분을 추출하여 얻어질 수 있다. In addition, the extract may be obtained from Hovenia dulcis ) can be extracted by using unrestricted ground or underground part, but it can be obtained by extracting the stem part specifically because the anti-allergy effect of the stem part extract is excellent.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 조성물 총 중량에 대하여 0.001% 내지 80%의 지구자 추출물을 포함할 수 있다. In a composition that is an aspect of the invention, the composition may comprise from 0.001% to 80% of Jim's extract, based on the total weight of the composition.
본 발명의 일 관점인 조성물이 상기 지구자 추출물을 0.001% 미만으로 함유하면 알러지 예방 등에 효과가 미미하며, 80%를 초과하여 함유하는 경우 다른 조성에 영향을 미쳐서 적절하지 않다. 상기와 같은 관점에서, 상기 조성물은 지구자 추출물을 조성물 총 중량에 대하여 0.005 내지 78 중량%, 0.01 내지 76 중량%, 0.05 내지 74 중량%, 0.1 내지 72 중량%, 0.5 내지 70 중량%, 1 내지 68 중량% 또는 5 내지 66 중량%으로 포함할 수 있다. If the composition of the present invention is contained in an amount of less than 0.001%, the effect of preventing the allergy is insignificant. If the composition contains more than 80%, it is not suitable because it affects other compositions. In view of the above, the composition may contain 0.005-78 wt%, 0.01-76 wt%, 0.05-74 wt%, 0.1-72 wt%, 0.5-70 wt%, 1 - 68% by weight or 5 to 66% by weight.
본 발명의 일 관점인 조성물에 있어서, 상기 알러지는 알러지 비염(allergic rhinitis), 알러지 천식(bronchial asthma), 고초열(hay fever), 퀸케부종(Quincke's edema), 아나필락시스(anaphylaxis) 쇼크, 두드러기(hives), 알러지성 결막염 (allergic conjunctivitis), 알러지성 각막염 (allergic keratitis) 또는 아토피 피부염(atopic dermatitis)일 수 있다. In one aspect of the invention, the allergic is selected from the group consisting of allergic rhinitis, bronchial asthma, hay fever, Quincke's edema, anaphylaxis shock, hives ), Allergic conjunctivitis, allergic keratitis, or atopic dermatitis.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 히스타민 생성을 억제할 수 있다. 본 발명의 일 관점인 상기 조성물은 히스타민 자체의 생성을 억제 또는 저해시킬 수 있거나 또는 본 발명 조성물에 의해 미미하게 생성된 히스타민의 활성을 억제 또는 저해시킬 수 있다. 본 발명의 일 관점인 상기 조성물은 또한 히스타민을 생성시키는 전단계 (up-stream)의 효소 또는 단백질의 활성을 억제 또는 저해시킬 수 있다. In one aspect of the present invention, the composition may inhibit histamine production. In one aspect of the present invention, the composition may inhibit or inhibit the production of histamine itself or may inhibit or inhibit the activity of the histamine produced by the composition of the present invention. The composition, which is an aspect of the present invention, may also inhibit or inhibit the activity of an up-stream enzyme or protein that produces histamine.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 TNF-α (Tumor Necrosis Factor-α)의 생성을 억제할 수 있다. 본 발명의 일 관점인 상기 조성물은 TNF-α자체의 생성을 억제 또는 저해시킬 수 있거나 또는 본 발명 조성물에 의해 미미하게 생성된 TNF-α 활성을 억제 또는 저해시킬 수 있다. 본 발명의 일 관점인 상기 조성물은 또한 TNF-α 생성시키는 전단계 (up-stream)의 효소 또는 단백질의 활성을 억제 또는 저해시킬 수 있다.In one aspect of the present invention, the composition may inhibit the production of TNF-alpha (Tumor Necrosis Factor-alpha). In one aspect of the present invention, the composition may inhibit or inhibit the production of TNF- [alpha] itself or may inhibit or inhibit TNF- [alpha] activity generated insignificantly by the composition of the present invention. The composition, which is an aspect of the present invention, may also inhibit or inhibit the activity of an up-stream enzyme or protein that produces TNF- [alpha].
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 인터루킨의 생성을 억제할 수 있다. 본 발명의 일 관점인 상기 조성물은 인터루킨 자체의 생성을 억제 또는 저해시킬 수 있거나 또는 본 발명 조성물에 의해 미미하게 생성된 인터루킨의 활성을 억제 또는 저해시킬 수 있다. 본 발명의 일 관점인 상기 조성물은 또한 인터루킨을 생성시키는 전단계 (up-stream)의 효소 또는 단백질의 활성을 억제 또는 저해시킬 수 있다. 본 발명의 일 관점인 조성물에 있어서, 상기 인터루킨은 인터루킨 4, 인터루킨 5, 인터루킨 13을 포함하지만, 이에 제한되는 것은 아니다. In the composition according to one aspect of the present invention, the composition can inhibit the production of interleukin. In one aspect of the present invention, the composition may inhibit or inhibit the production of interleukin itself, or may inhibit or inhibit the activity of interleukins that are minimally produced by the composition of the present invention. The composition, which is an aspect of the present invention, may also inhibit or inhibit the activity of an up-stream enzyme or protein that produces interleukin. In one aspect of the present invention, the interleukin includes, but is not limited to, interleukin 4,
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 TARC(Thymus and activation-regulated chemokine/CCL17)의 생성을 억제할 수 있다. TARC는 백혈구 유주(이동)에 관여하는 케모카인의 일종이다. 구체적으로, 아토피피부염은, TARC의 수용체 CCR4를 발현하는 Th2세포에 대해 유주(이동)활성을 갖고 있는데, 피부의 표피각화세포에서 그리고 말초혈의 단핵구에서 TARC의 생성이 항진하고, 과잉으로 생성된 TARC가 CCR4를 발현하는 Th2세포를 피부로 이동시켜, 병태를 악화시킨다고 여겨지고 있다. 아토피피부염 환자의 혈청 내 TARC 수치는, 다른 피부질환 환자와 비교하여 유의하게 높은 값을 나타내고, 아토피 피부염의 중증도에 따라 증가한다. 그러므로, 아토피 피부염의 병태를 객관적으로 평가할 수 있는 주요 지표가 될 수 있다. 본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 TARC 생성을 억제할 수 있다. 본 발명의 일 관점인 상기 조성물은 TARC 자체의 생성을 억제 또는 저해시킬 수 있거나 또는 본 발명 조성물에 의해 미미하게 생성된 TARC의 활성을 억제 또는 저해시킬 수 있다. 본 발명의 일 관점인 상기 조성물은 또한 TARC을 생성시키는 전단계 (up-stream)의 효소 또는 단백질의 활성을 억제 또는 저해시킬 수 있다.
In one aspect of the present invention, the composition may inhibit the production of TARC (Thymus and activation-regulated chemokine / CCL17). TARC is a type of chemokine involved in leukocyte migration (migration). Specifically, atopic dermatitis has migrating (migrating) activity to Th2 cells expressing TARC receptor CCR4. In the epidermal keratinocytes of skin and mononuclear cells of peripheral blood, TARC production is exaggerated, and excess production TARC is thought to cause CCR4-expressing Th2 cells to migrate to the skin and worsen the condition. TARC levels in serum of patients with atopic dermatitis are significantly higher than those of other skin diseases and increase with the severity of atopic dermatitis. Therefore, it can be a key indicator for objectively evaluating the condition of atopic dermatitis. In one aspect of the present invention, the composition may inhibit TARC production. One aspect of the present invention is that the composition may inhibit or inhibit the production of TARC itself or may inhibit or inhibit the activity of TARC that is generated negligible by the composition of the present invention. The composition, which is an aspect of the present invention, may also inhibit or inhibit the activity of an up-stream enzyme or protein that produces TARC.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
<< 실시예Example 1> 지구자 추출물의 제조 1> Manufacture of endophthalmitis extract
지구자(Hovenia dulcis)는 서울시 경동시장에서 구입한 것을 사용하였으며, 이들을 세척하고 건조하여 사용하였다. 지구자 줄기를 분쇄하여 추출용기에 넣고 적당량의 에탄올을 넣었다. 이들을 상온에서 7일 동안 방치한 후, 거름종이로 여과하여 본 발명에 쓰인 추출물을 얻었다. 구체적으로, 지구자 30 g에 700 mL 에탄올을 추가 후 추출 및 농축하여 추출물 1.1 g을 얻었다. 이렇게 얻어진 추출물을 DMSO (Dimethyl sulfoxide) 에 녹인 후, 하기 실험예에서 이용하였다.
Hovenia dulcis was purchased from Kyungdong market in Seoul, and they were washed and dried. The stomach stem was crushed and placed in an extraction vessel and an appropriate amount of ethanol was added. These were allowed to stand at room temperature for 7 days, and then filtered with a filter paper to obtain an extract of the present invention. Specifically, 700 mL of ethanol was added to 30 g of the mitochondria, followed by extraction and concentration to obtain 1.1 g of the extract. The thus-obtained extract was dissolved in DMSO (dimethyl sulfoxide) and used in the following experimental examples.
<< 실험예Experimental Example 1> 비만세포의 과립 내 존재하는 1> Present in the granules of mast cells 알러지allergy 유발물질의 분비를 억제 Suppress secretion of inducing substances
본 발명자들은 지구자 추출물이 비만세포의 과립 내 존재하는 알러지 유발물질의 분비를 억제하는지 여부를 아래와 같이 확인하였다(Jeong. H. J. et al., Cytokine, 18:252-9, 2002). The inventors of the present invention have confirmed the following whether jejunal extract inhibits the secretion of allergens present in granules of mast cells (Jeong, H. J. et al., Cytokine, 18: 252-9, 2002).
래트의 호염기성 (Rat basophilic leukocyte, RBL-2H3, American Type Culture Collection, USA) 비만세포를 항생제와 10% 우혈청이 존재하는 최소배지에서 배양하였다. 배양 후 상기 세포를 트립신으로 수거한 후, 24-공 평판배양기(24-well microtiter plate)에 2×105 세포/ 공(well)이 되도록 넣고, 80% 자랄 때까지 배양하였다. 이렇게 배양한 세포를 PIPES 완충액(25 mM PIPES, pH 7.2, 159 mM NaCl, 5 mM KCl, 0.4 mM MgCl2, 1 mM CaCl2, 5.6 mM glucose, 및 0.1% BSA)으로 치환시킨 후, 상기 <실시예 1>에 의해 얻어진 지구자 추출물을 5, 10, 20 μg/ml 각각의 농도로 첨가하고 1시간 동안 배양시켰다. 1 시간 후, DNP-BSA를 최종농도 200 μg/ml로 첨가하고 30 분간 자극을 유도하였다. 알러지 유도물질의 분비 정도는 배지중에 분비된 탈과립의 표식자인 베타 헥소스아미니데이즈 (β-hexosaminidase)의 활성을 측정하여 결정하였으며, 베타 헥소스아미니데이즈 (β-hexosaminidase)의 활성은 p-니트로페닐-아세틸-β-D-글루코사미나이드(p-nitrophenyl-acetyl-β-D-glucosaminide)로부터 유리된 p-니트로페닐(p-nitrophenol)의 양으로 결정하였다(Funaba M. et al., Cell Biol. Int., 27:879-85, 2003). Rat basophilic leukocyte (RBL-2H3, American Type Culture Collection, USA) mast cells were cultured in a minimal medium containing antibiotics and 10% bovine serum. After culturing, the cells were harvested by trypsin, and the cells were added to a 24-well microtiter plate at 2 × 10 5 cells / well and cultured to 80% growth. The thus-cultured cells were substituted with PIPES buffer (25 mM PIPES, pH 7.2, 159 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 1 mM CaCl 2 , 5.6 mM glucose, and 0.1% BSA) The extracts obtained from Example 1 were added at concentrations of 5, 10 and 20 μg / ml, respectively, and cultured for 1 hour. One hour later, DNP-BSA was added to a final concentration of 200 μg / ml and stimulation was induced for 30 minutes. The degree of secretion of allergen-inducing substances was determined by measuring the activity of β-hexosaminidase, a marker of degranulation secreted in the medium. The activity of β-hexosaminidase was determined by p- The amount of p-nitrophenol liberated from p-nitrophenyl-acetyl-β-D-glucosaminide was determined by the method of Funaba M. et al. Cell Biol. Int., 27: 879-85, 2003).
그 결과, 도 1에 나타난 바와 같이, 지구자 추출물이 비만세포의 과립 내 존재하는 알러지 유발물질의 분비를 억제하는 효과가 우수함을 확인할 수 있었다.
As a result, as shown in FIG. 1, it was confirmed that the mitochondrial extract had an excellent effect of inhibiting the secretion of allergens present in granules of mast cells.
<< 실험예Experimental Example 2> 히스타민 생성 억제 2> inhibition of histamine production
상기 <실시예 1>을 통해 얻은 지구자 추출물이 히스타민의 생성을 억제하는지 여부를 아래와 같이 확인하였다. It was confirmed as follows whether or not the endoplasmic reticulum extract obtained through Example 1 suppresses histamine production.
2.5%의 우태아 혈청이 함유된 DMEM(Dulbecco's Modified Eagle's Media) 배지가 들어있는 24-공 평판배양기(24-well microtiter plate)에 RBL-2H3 비만세포를 2×105 세포/ 공(well)이 되도록 넣고, 80%로 자랄 때까지 배양시켰다. 그 후, 상기 <실험예 1>로부터 얻어진 지구자 추출물 5, 10, 20 μg/ml의 농도 각각을 무혈청 DMEM 배지에 첨가하고, 비만세포를 24시간 동안 배양시켰다. 비만세포에 DNP-BSA를 30분간 처리한 다음 세포배양액을 채취하여 원심분리하고 상등액만 수확하였다. 상등액 중의 히스타민의 양은 EIA 키트 (Bertin Pharma, France)를 이용하여 확인하였다. RBL-2H3 mast cells were cultured in a 24-well microtiter plate containing 2.5% fetal bovine serum (DMEM) (Dulbecco's Modified Eagle's Media) at 2 × 10 5 cells / well , And cultured until it grew to 80%. Then, the JEM extracts obtained from Experimental Example 1 were added to serum-free DMEM medium at 5, 10 and 20 μg / ml, respectively, and mast cells were cultured for 24 hours. The mast cells were treated with DNP-BSA for 30 minutes. Then, the cell culture was collected, centrifuged, and the supernatant was harvested. The amount of histamine in the supernatant was determined using an EIA kit (Bertin Pharma, France).
그 결과, 도 2에서 보인 바와 같이, 지구자 추출물은 히스타민의 생성을 억제하는 효과가 매우 우수함을 알 수 있었다.
As a result, as shown in Fig. 2, it was found that the mitochondrial extract had an excellent effect of inhibiting histamine production.
<< 실험예Experimental Example 3> 3> TNFTNF -α 생성 억제-α production inhibition
상기 <실시예 1>을 통해 얻은 지구자 추출물이 TNF-α 생성을 억제하는지 여부를 아래와 같이 확인하였다. It was confirmed as follows whether or not the endoplasmic reticulum extract obtained in Example 1 suppresses TNF-α production.
2.5%의 우태아 혈청이 함유된 DMEM(Dulbecco's Modified Eagle's Media) 배지가 들어있는 24-공 평판배양기(24-well microtiter plate)에 RBL-2H3 비만세포를 2×105 세포/ 공(well)이 되도록 넣고, 80% 자랄 때까지 배양시켰다. 그 후, 상기 <실시예 1>로부터 얻어진 지구자 추출물 5, 10, 20 μg/ml의 농도 각각을 무혈청 DMEM 배지에 첨가하고, 비만세포를 24시간 동안 배양시켰다. 비만세포에 DNP-BSA를 30분 처리한 다음 세포배양액을 채취하여 원심분리하고 상등액만 수확하였다. 상등액 중의 TNF-α양은 ELISA 키트 (abcam, UK)를 이용하여 확인하였다. RBL-2H3 mast cells were cultured in a 24-well microtiter plate containing 2.5% fetal bovine serum (DMEM) (Dulbecco's Modified Eagle's Media) at 2 × 10 5 cells / well , And cultured to 80% growth. Then, the JEM extractives obtained from <Example 1> at 5, 10 and 20 μg / ml were added to serum-free DMEM medium, and the mast cells were cultured for 24 hours. The mast cells were treated with DNP-BSA for 30 minutes, then the cell culture was centrifuged and only the supernatant was harvested. The amount of TNF-? In the supernatant was confirmed using an ELISA kit (abcam, UK).
그 결과, 도 3에 보이는 바와 같이, 지구자 추출물은 TNF-α생성을 억제함을 확인할 수 있었다.
As a result, as shown in Fig. 3, it was confirmed that extracellular fluid extract inhibited TNF-α production.
<< 실험예Experimental Example 4> 인터루킨-4 생성 억제 4> inhibition of interleukin-4 production
상기 <실시예 1>을 통해 얻은 지구자 추출물이 인터루킨-4의 생성을 억제하는지 여부를 아래와 같이 확인하였다. It was confirmed as follows whether or not the endoplasmic reticulum extract obtained through Example 1 inhibits the production of interleukin-4.
2.5%의 우태아 혈청이 함유된 DMEM(Dulbecco's Modified Eagle's Media) 배지가 들어있는 24-공 평판배양기(24-well microtiter plate)에 RBL-2H3 비만세포를 2×105 세포/ 공(well)이 되도록 넣고, 80% 자랄 때까지 배양시켰다. 그 후, 상기 <실시예 1>로부터 얻어진 지구자 추출물 5, 10, 20 μg/ml의 농도 각각을 무혈청 DMEM 배지에 첨가하고, 비만세포를 24시간 동안 배양시켰다. 비만세포에 DNP-BSA를 30분 처리한 다음 세포배양액을 채취하여 원심분리하고 상등액만 수확하였다. 상등액 중의 인터루킨-4의 양은 ELISA 키트 (abcam, UK)를 이용하여 확인하였다. RBL-2H3 mast cells were cultured in a 24-well microtiter plate containing 2.5% fetal bovine serum (DMEM) (Dulbecco's Modified Eagle's Media) at 2 × 10 5 cells / well , And cultured to 80% growth. Then, the JEM extractives obtained from <Example 1> at 5, 10 and 20 μg / ml were added to serum-free DMEM medium, and the mast cells were cultured for 24 hours. The mast cells were treated with DNP-BSA for 30 minutes, then the cell culture was centrifuged and only the supernatant was harvested. The amount of interleukin-4 in the supernatant was determined using an ELISA kit (abcam, UK).
그 결과, 도 4에 보이는 바와 같이, 지구자 추출물은 인터루킨-4의 생성을 억제함을 확인할 수 있었다.
As a result, as shown in FIG. 4, it was confirmed that the extract of endospores inhibits the production of interleukin-4.
<< 실험예Experimental Example 5> 5> TARCTARC 생성 억제 Generation inhibition
상기 <실시예 1>을 통해 얻은 지구자 추출물이 TARC의 생성을 억제하는지 여부를 아래와 같이 확인하였다. It was confirmed whether or not the endoplasmic reticulum extract obtained from Example 1 suppressed TARC production as follows .
2.5%의 우태아 혈청이 함유된 DMEM(Dulbecco's Modified Eagle's Media) 배지가 들어있는 24-공 평판배양기(24-well microtiter plate)에 HaCaT 인체 각질형성세포를 2×105 세포/ 공(well)이 되도록 넣고, 90% 자랄 때까지 배양시켰다. 그 후, 상기 <실시예 1>로부터 얻어진 지구자 추출물 1, 5, 10 μg/ml의 농도 각각을 TNF-α 및 IFN-γ 10 ng/ml와 함께 무혈청 DMEM 배지에 첨가하고, 인체 각질형성세포를 24시간 동안 배양시켰다. 24시간 경과 후, 세포배양액을 채취하여 원심분리하고 상등액만 수확하였다. 상등액 중의 TARC의 양은 ELISA 키트(abcam, UK)를 이용하여 확인하였다. HaCaT human keratinocytes were seeded at 2 × 10 5 cells / well in a 24-well microtiter plate containing 2.5% fetal bovine serum-containing DMEM (Dulbecco's Modified Eagle's Media) , And cultured to 90% growth. Then, each of 1, 5, and 10 μg / ml of JEM extract obtained from Example 1 was added to serum-free DMEM medium together with TNF-α and IFN-
그 결과, 도 5에 보이는 바와 같이, 지구자 추출물은 TARC의 생성을 억제하는 효과가 매우 우수함을 알 수 있었다.
As a result, as shown in FIG. 5, it was found that the mitochondrial extract greatly exerted an effect of inhibiting TARC production.
이하, 본 발명에 따른 조성물의 제형 예를 설명하나, 약학 조성물 및 화장료 조성물은 여러 가지 제형으로 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, a formulation example of the composition according to the present invention will be described. However, the pharmaceutical composition and the cosmetic composition can be applied to various formulations, which are not intended to limit the present invention but merely to illustrate the present invention.
[제제예 1] 연질캅셀제[Formulation Example 1] Soft capsule
지구자 추출물 150 mg, 팜유 2 mg, 팜경화유 8 mg, 황납 4 mg 및 레시틴 6 mg을 혼합하고, 통상의 방법에 따라 1 캡슐당 400 mg씩 충진하여 연질캅셀을 제조하였다.A soft capsule was prepared by mixing 150 mg of Zygomycota extract, 2 mg of palm oil, 8 mg of palm kernel oil, 4 mg of yellow radish and 4 mg of lecithin and 400 mg per capsule according to a conventional method.
[제제예 2] 정제[Formulation Example 2] Tablets
지구자 추출물 150 mg, 포도당 100 mg, 홍삼추출물 50 mg, 전분 96 mg 및 마그네슘 스테아레이트 4 mg을 혼합하고 30% 에탄올을 40 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하고 타정기를 이용하여 정제로 타정하였다.The granules were formed by mixing 150 mg of the extract from the kidneys, 100 mg of glucose, 50 mg of red ginseng, 96 mg of starch and 4 mg of magnesium stearate, and 30% ethanol was added thereto, followed by drying at 60 ° C. Tablets were tableted.
[제제예 3] 과립제[Formulation Example 3] Granules
지구자 추출물 150 mg, 포도당 100 mg, 홍삼추출물 50 mg 및 전분 600 mg을 혼합하고 30% 에탄올을 100 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하여 과립을 형성한 다음 포에 충진하였다. 내용물의 최종 중량은 1 g으로 하였다.The granules were formed by mixing 150 mg of Zygomoe extract, 100 mg of glucose, 50 mg of red ginseng extract and 600 mg of starch and 100 mg of 30% ethanol, and dried at 60 ° C. to form granules, which were then filled into bubbles. The final weight of the contents was 1 g.
[제제예 4] 드링크제[Formulation Example 4] Drinking agent
지구자 추출물 150 mg, 포도당 10 g, 홍삼추출물 50 mg, 구연산 2 g 및 정제수 187.8 g을 혼합하고 병에 충진하였다. 내용물의 최종 용량은 200 ml로 하였다.150 mg of Zygomycota extract, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid and 187.8 g of purified water were mixed and filled in a bottle. The final volume of the contents was adjusted to 200 ml.
[제제예 5] 건강 식품의 제조[Formulation Example 5] Preparation of health food
지구자 추출물 .............................. 1000 ㎎ Platycodon extract .............................. 1000 mg
비타민 혼합물 Vitamin mixture
비타민 A 아세테이트.......................70 ㎍ Vitamin A Acetate ....................... 70 ㎍
비타민 E ............................................ 1.0 ㎎ Vitamin E ............................................ 1.0 mg
비타민 B1........................................... 0.13 ㎎ Vitamin B1 ........................................... 0.13 mg
비타민 B2 .......................................... 0.15 ㎎ Vitamin B2 .......................................... 0.15 mg
비타민 B6........................................... 0.5 ㎎ Vitamin B6 ........................................... 0.5 mg
비타민 B12......................................... 0.2 ㎍ Vitamin B12 .............................. 0.2 g
비타민 C............................................. 10 ㎎ Vitamin C ............................................. 10 mg
비오틴.................................................. 10 ㎍ Biotin ................................................. 10 [mu] g
니코틴산아미드.................................. 1.7 ㎎ Nicotinic acid amide .................................. 1.7 mg
엽산...................................................... 50 ㎍ Folic acid ................................................. ..... 50 μg
판토텐산 칼슘.................................... 0.5 ㎎ Calcium pantothenate .................................... 0.5 mg
무기질 혼합물 Mineral mixture
황산제1철.......................................... 1.75 ㎎ Ferrous sulfate .......................................... 1.75 mg
산화아연.............................................. 0.82 ㎎ Zinc oxide ............................................ 0.82 mg
탄산마그네슘...................................... 25.3 ㎎ Magnesium carbonate ...................................... 25.3 mg
제1인산칼륨.......................................... 15 ㎎ Potassium Phosphate ......................................... 15 mg
제2인산칼슘.......................................... 55 ㎎ Secondary calcium phosphate ...................................... 55 mg
구연산칼륨............................................ 90 ㎎ Potassium citrate ............................................ 90 mg
탄산칼슘.............................................. 100 ㎎ Calcium carbonate .............................................. 100 mg
염화마그네슘..................................... 24.8 ㎎ Magnesium chloride ..................................... 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
[제제예 6] 건강 음료의 제조 [Formulation Example 6] Preparation of health drink
지구자 추출물............................ 1000 ㎎ Platycodon extract ............................ 1000 mg
구연산..................................................... 1000 ㎎ Citric acid ................................................. ... 1000 mg
올리고당..................................................... 100 g oligosaccharide................................................. .... 100 g
매실농축액..................................................... 2 g Plum concentrate ................................................ ..... 2 g
타우린............................................................ 1 g Taurine ................................................. ........... 1 g
정제수를 가하여 전체......................... 900 ㎖ Purified water was added to the mixture to complete 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비율을 임의로 변형 실시하여도 무방하다. 본 발명이 속한 기술 분야에서 통상의 지식을 가진 자라면 상기 내용을 바탕으로 본 발명의 범주 내에서 다양한 응용 및 변형을 행하는 것이 가능할 것이다. Although the composition ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the blending ratio according to the regional or national preference such as the demand level, the demanding country, the use purpose, and the like. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
[제형예 1] 유연화장수(스킨로션)[Formulation Example 1] Softening lotion (skin lotion)
[제형예 2] 영양화장수(밀크로션)[Formulation Example 2] Nutritional lotion (Milk lotion)
[제형예 3] 영양크림[Formulation Example 3] Nourishing cream
[제형예 4] 마사지 크림[Formulation Example 4] Massage cream
[제형예 5] 팩[Formulation Example 5] Pack
[제형예 6] 연고[Formulation Example 6] ointment
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (10)
A pharmaceutical composition for preventing or treating allergy comprising an extract of Hovenia dulcis stem as an active ingredient.
A food composition for preventing or ameliorating allergy comprising an extract of Hovenia dulcis stem as an active ingredient.
A cosmetic composition for improving or alleviating allergies comprising an extract of Hovenia dulcis stem as an active ingredient.
상기 추출물은 물, C1-C6 알콜, 및 이들의 조합으로 구성된 그룹에서 선택된 용매의 조추출물인, 조성물.
4. The method according to any one of claims 1 to 3,
Wherein the extract is a crude extract of a solvent selected from the group consisting of water, C 1 -C 6 alcohols, and combinations thereof.
상기 조성물은 조성물 총 중량에 대하여 0.001% 내지 80%의 호베니아 덜시스(Hovenia dulcis) 줄기의 추출물을 포함하는, 조성물.
4. The method according to any one of claims 1 to 3,
Wherein said composition comprises from 0.001% to 80% of Hovenia dulcis stem extracts based on the total weight of the composition.
상기 알러지는 알러지 비염(allergic rhinitis), 알러지 천식(bronchial asthma), 고초열(hay fever), 퀸케부종(Quincke's edema), 아나필락시스(anaphylaxis), 두드러기(hives), 알러지성 결막염 (allergic conjunctivitis), 알러지성 각막염 (allergic keratitis) 또는 아토피 피부염(atopic dermatitis)의 질환을 포함하는, 조성물.
4. The method according to any one of claims 1 to 3,
The allergies may be selected from the group consisting of allergic rhinitis, bronchial asthma, hay fever, Quincke's edema, anaphylaxis, hives, allergic conjunctivitis, allergic rhinitis, Allergic keratitis or atopic dermatitis. ≪ RTI ID = 0.0 > 21. < / RTI >
상기 조성물은 히스타민 생성을 억제하는, 조성물.
4. The method according to any one of claims 1 to 3,
Wherein said composition inhibits histamine production.
상기 조성물은 TNF-α(Tumor Necrosis Factor-α)의 생성을 억제하는, 조성물.
4. The method according to any one of claims 1 to 3,
Wherein said composition inhibits the production of TNF-alpha (Tumor Necrosis Factor-alpha).
상기 조성물은 인터루킨의 생성을 억제하는, 조성물.
4. The method according to any one of claims 1 to 3,
Wherein the composition inhibits the production of interleukins.
상기 조성물은 TARC(Thymus and activation-regulated chemokine/CCL17)의 생성을 억제하는, 조성물.4. The method according to any one of claims 1 to 3,
Wherein said composition inhibits the production of TARC (Thymus and activation-regulated chemokine / CCL17).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130101689A KR101534755B1 (en) | 2013-08-27 | 2013-08-27 | Composition for anti-allergy containing oriental raisin tree extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130101689A KR101534755B1 (en) | 2013-08-27 | 2013-08-27 | Composition for anti-allergy containing oriental raisin tree extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150024598A KR20150024598A (en) | 2015-03-09 |
KR101534755B1 true KR101534755B1 (en) | 2015-07-09 |
Family
ID=53021144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130101689A KR101534755B1 (en) | 2013-08-27 | 2013-08-27 | Composition for anti-allergy containing oriental raisin tree extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101534755B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105267271A (en) * | 2015-10-28 | 2016-01-27 | 葛善文 | Traditional Chinese medicine composition for treating viral keratitis and preparation method and application of traditional Chinese medicine composition |
KR101881758B1 (en) * | 2016-07-29 | 2018-07-25 | 한국과학기술연구원 | Composition for anti-allergy comprising larix sibirica extract |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050047058A (en) * | 2005-04-26 | 2005-05-19 | 주식회사 코리바이오라이프 | A herb extract |
JP2009292735A (en) * | 2008-06-02 | 2009-12-17 | Kinjirushi Kk | Allergic disease-suppressing composition |
-
2013
- 2013-08-27 KR KR1020130101689A patent/KR101534755B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050047058A (en) * | 2005-04-26 | 2005-05-19 | 주식회사 코리바이오라이프 | A herb extract |
JP2009292735A (en) * | 2008-06-02 | 2009-12-17 | Kinjirushi Kk | Allergic disease-suppressing composition |
Non-Patent Citations (4)
Title |
---|
Clinical and Experimental Allergy, Vol.20, pp.501-508 (2000) * |
Clinical and Experimental Allergy, Vol.20, pp.501-508 (2000)* |
Natural Product Sciences, Vol.9, No.3, pp.143-153 (2003) * |
Natural Product Sciences, Vol.9, No.3, pp.143-153 (2003)* |
Also Published As
Publication number | Publication date |
---|---|
KR20150024598A (en) | 2015-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100615389B1 (en) | Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease | |
US11166934B2 (en) | Pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy including baicalein as active ingredient | |
KR101571131B1 (en) | Composition for anti-allergy containing paeonia anomala extract | |
KR101779085B1 (en) | Anti-allergic composition comprising sphallerocarpus plant extracts | |
KR102218823B1 (en) | Composition for anti-allergy comprising extract of lithospermum erythrorhizon | |
KR101704539B1 (en) | Composition for anti-allergy and skin hydration comprising sedum kamtschaticum extracts | |
KR101534755B1 (en) | Composition for anti-allergy containing oriental raisin tree extract | |
KR20180106155A (en) | Whitening and moisturizing functional composition comprising a fermentation material of a natural mixture | |
KR101484948B1 (en) | Composition for anti-allergy containing rose mukdenia extract | |
KR101367961B1 (en) | Compositoin for Improving Atopic Dermatitis | |
KR101753687B1 (en) | Composition for anti-allergy and skin hydration comprising fraxinus rhynchophylla extracts | |
KR101593624B1 (en) | Composition for reducing irritation and inflammation in skin | |
KR102514502B1 (en) | Composition for Improving for Atopic Dermatitis, Pruritis, and Inflammation Comprising Sparasis crispa, vegetable worms, and Tuber melanosporum as Active Ingredient | |
KR101718854B1 (en) | Cosmetic composition containing Ligustrum lucidum Aiton, Astragalus membranaceus Bunge, Citrus unshin Markovich, Angelica dahurica root extract for moisturizing the skin | |
KR101620153B1 (en) | Composition for preventing or treating ostarthritis comprising Glehnia littoralis | |
KR101618309B1 (en) | Composition for anti-allergy and skin hydration comprising pterocarpus santalinus extracts | |
KR20180013483A (en) | Composition for anti-allergy comprising larix sibirica extract | |
KR101446295B1 (en) | Composition for anti-aging containing sargassum yezoense extract | |
JP2010070531A (en) | DEGRANULATION INHIBITOR OBTAINED FROM NATURAL EXTRACT, beta-HEXOSAMINIDASE RELEASE INHIBITOR, ANTIALLERGIC OR ANTIINFLAMMATORY FOOD, DRUG, ANIMAL FEED COMPOSITION AND COSMETIC RAW MATERIAL COMPOSITION | |
KR101739425B1 (en) | Composition for preventing or improving inflammatory disorders comprising fraction of Oenanthe javanica ethanol extract as effective component | |
KR20150087657A (en) | Composition comprising the purified extract of Eriobotrya japonica Radix for immune activity | |
KR101986008B1 (en) | Pharmaceutical composition for preventing or treating atopic dermatitis comprising extract of resveratrol-enriched rice or resveratrol enriched rice callus as an active ingredient | |
KR101330044B1 (en) | Composition for improving obesity including compounds from cordyceps militaris having anti-obesity activity | |
KR102014962B1 (en) | Composition for antiinflammation containing extract of soybean pod | |
KR101997033B1 (en) | Composition for antiinflammation containing extract of soybean root |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20180703 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190701 Year of fee payment: 5 |